ClinicalTrials.gg
CompletedNCT05061719Updated Nov 3, 2025Results posted

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Phase 3 interventional study of Lumateperone in Major Depressive Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 109 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
812
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
2nd of 52
812 · median 203
Started
2021
with 5 others
Phase 3
23 of 59
5 open now
Registered
44th of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2021, is one of 23 in phase 3, and was the 44th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.

Read the detailed description

At the Screening/Baseline Visit (Visit 1/Day 1), which is the same visit as Visit 8/Day 43 of the lead-in study, eligible patients will receive open-label lumateperone 42 mg once daily for approximately 26 weeks. Patients will continue their background ADT from the lead-in study. Patients will be seen for weekly visits through Visit 5/Week 4. Thereafter, visits will occur every two weeks. A Safety Follow-up visit will occur on Visit 17/Day 197, approximately 2 weeks after the last dose of open-label lumateperone 42 mg.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Adjunctive MDD Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the Investigator, patients must have safely completed the lead-in study.
  2. Patient is taking their ADT as prescribed from the lead-in study.

Exclusion criteria

Exclusion Criteria:

  1. In the opinion of the Investigator, the patient is unable to comply with study procedures or judged to be inappropriate for the study.
  2. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of her/his participation in the study or is considered to be an imminent danger to her/himself or others, and/or:

    1. At the Screening/Baseline Visit, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the C SSRS "Since Last Visit" version;
    2. At the Screening/Baseline visit, the patient scores ≥ 5 on the MADRS Item 10 (Suicidal Thoughts).
  3. Based on the Investigator's clinical judgement, any abnormal clinical laboratory test or results obtained throughout the lead-in study that are considered and preclude safe participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
812 participants (actual)

Study arms

  • Experimental
    Lumateperone 42 mg

    Drug: Lumateperone

Interventions

  • Lumateperone 42 mg capsules administered orally, once daily

06

What researchers measure

Primary outcomes

  1. The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events

    An AE that occurs during the Open-label Treatment Period will be considered a treatment-emergent AE (TEAE) if it was not present before the date of the first dose of open-label lumateperone or was present before the date of the first dose of open-label lumateperone but changed in severity during the Open-label Treatment Period.

    Time frame: 26 weeks

Secondary outcomes

  1. Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Montgomery-Åsberg Depression Rating Scale

    The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: 32 weeks

  2. Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Clinical Global Impression Scale-Severity

    The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not ta all ill) to 7 (among the most extremely ill patients).

    Time frame: 32 weeks

07

Results

Posted Nov 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 42 mg
Started809
Completed684
Not completed125
Withdrew: Adverse event60
Withdrew: Death1
Withdrew: Lack of efficacy7
Withdrew: Lost to follow-up5
Withdrew: Pregnancy1
Withdrew: Protocol violation8
Withdrew: Withdrawal by subject41
Withdrew: Site closure2

Outcome measures

PrimaryThe Number and Percentage of Patients Reporting Treatment Emergent Adverse Events

An AE that occurs during the Open-label Treatment Period will be considered a treatment-emergent AE (TEAE) if it was not present before the date of the first dose of open-label lumateperone or was present before the date of the first dose of open-label lumateperone but changed in severity during the Open-label Treatment Period.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events
ParticipantsLumateperone 42 mg
The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events548
SecondaryChange From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Montgomery-Åsberg Depression Rating Scale

The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
32 weeks
Reported as:
Mean · score on a scale
Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Montgomery-Åsberg Depression Rating Scale
score on a scaleLumateperone 42 mg
Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Montgomery-Åsberg Depression Rating Scale-21.7 ± 8.39
SecondaryChange From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Clinical Global Impression Scale-Severity

The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not ta all ill) to 7 (among the most extremely ill patients).

Time frame:
32 weeks
Reported as:
Mean · score on a scale
Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Clinical Global Impression Scale-Severity
score on a scaleLumateperone 42 mg
Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Clinical Global Impression Scale-Severity-2.5 ± 1.19

Adverse events

Collected over From signing ICF until end of study procedures (~28 weeks), including 26 weeks of open-label treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 42 mg1/809 (0.1%)8/809 (1%)322/809 (39.8%)
Most frequent serious events
Most frequent serious events
EventLumateperone 42 mg
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/809
Alcohol PoisoningInjury, poisoning and procedural complications1/809
ContusionInjury, poisoning and procedural complications1/809
Spinal compression fractureInjury, poisoning and procedural complications1/809
Biliary colicHepatobiliary disorders1/809
Helicobacter gastritisInfections and infestations1/809
Postmenopausal haemorrhageReproductive system and breast disorders1/809
Most frequent other events
Most frequent other events
EventLumateperone 42 mg
HeadacheNervous system disorders134/809
DizzinessNervous system disorders86/809
Dry mouthGastrointestinal disorders65/809
NauseaGastrointestinal disorders62/809
SomnolenceNervous system disorders58/809
DiarrhoeaGastrointestinal disorders50/809
NasopharyngitisInfections and infestations42/809

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 42 mg
Mean46.2 ± 12.22
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 42 mg
Female549
Male260
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 42 mg
White703
Black or African American37
Asian61
Native Hawaiian or Other Pacific Islander2
Multiple4
Other2
Region of Enrollment
Region of Enrollment(participants)Lumateperone 42 mg
Sweden2
Hungary15
United States225
Czechia95
Poland147
Slovakia32
Bulgaria159
Germany25
India53
Argentina56
08

Study locations

109 sites
  • Clinical Site
    Phoenix, Arizona 85012, United States
  • Clinical Site
    Bentonville, Arkansas 72712, United States
  • Clinical Site
    Little Rock, Arkansas 72211, United States
  • Clinical Site
    Rogers, Arkansas 72758, United States
  • Clinical Site
    Culver City, California 90230, United States
  • Clinical Site
    Glendale, California 91206, United States
  • Clinical Site
    Newport Beach, California 92660, United States
  • Clinical Site
    Oceanside, California 92056, United States
  • Clinical Site
    Redlands, California 92374, United States
  • Clinical Site
    Riverside, California 92506, United States
  • Clinical Site
    San Diego, California 92103, United States
  • Clinical Site
    Sherman Oaks, California 91403, United States
  • Clinical Site
    Temecula, California 92951, United States
  • Clinical Site
    Upland, California 91786, United States
  • Clinical Site
    Fort Lauderdale, Florida 33319, United States
  • Clinical Site
    Jacksonville, Florida 32256, United States
  • Clinical Site
    Orlando, Florida 32801, United States
  • Clinical Site
    Palm Bay, Florida 32905, United States
  • Clinical Site
    West Palm Beach, Florida 33407, United States
  • Clinical Site
    Atlanta, Georgia 30328, United States
  • Clinical Site
    Atlanta, Georgia 30329, United States
  • Clinical Site
    Atlanta, Georgia 30331, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
  • Clinical Site
    Joliet, Illinois 60435, United States
  • Clinical Site
    Overland Park, Kansas 66211, United States
  • Clinical Site
    Gaithersburg, Maryland 20877, United States
  • Clinical Site
    Boston, Massachusetts 02131, United States
  • Clinical Site
    Flowood, Mississippi 39232, United States
  • Clinical Site
    Saint Charles, Missouri 63304, United States
  • Clinical Site
    Berlin, New Jersey 08009, United States
  • Clinical Site
    Toms River, New Jersey 08755, United States
  • Clinical Site
    Brooklyn, New York 11235, United States
  • Clinical Site
    Cedarhurst, New York 11516, United States
  • Clinical Site
    Mount Kisco, New York 10549, United States
  • Clinical Site
    Charlotte, North Carolina 28211, United States
  • Clinical Site
    Allentown, Pennsylvania 18104, United States
  • Clinical Site
    Media, Pennsylvania 19063, United States
  • Clinical Site
    Plymouth Meeting, Pennsylvania 19462, United States
  • Clinical Site
    Austin, Texas 78737, United States
  • Clinical Site
    Bellevue, Washington 98007, United States
  • Clinical Site
    Burgas, 8001, Bulgaria
  • Clinical Site
    Kazanlak, 6100, Bulgaria
  • Clinical Site
    Novi Iskar, 1282, Bulgaria
  • Clinical Site
    Pleven, 5809, Bulgaria
  • Clinical Site
    Plovdiv, 4004, Bulgaria
  • Clinical Site
    Rousse, 7003, Bulgaria
  • Clinical Site
    Sofia, 1408, Bulgaria
  • Clinical Site
    Sofia, 1680, Bulgaria
  • Clinical Site
    Targovishte, 7700, Bulgaria
  • Clinical Site
    Tsarev Brod, 9747, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5047, Bulgaria
  • Clinical Site
    Vratsa, 3001, Bulgaria
  • Clinical Site
    Brno, 60200, Czechia
  • Clinical site
    Brno, 615 00, Czechia
  • Clinical Site
    Hostivice, 253 01, Czechia
  • Clinical Site
    Ostrava, 708 00, Czechia
  • Clinical Site
    Pilsen, 301 00, Czechia
  • Clinical Site
    Prague, 100 00, Czechia
  • Clinical Site
    Prague, 160 00, Czechia
  • Clinical Site
    Prague, 186 00, Czechia
  • Clinical Site
    Helsinki, 00100, Finland
  • Clinical Site
    Oulu, 90100, Finland
  • Clinical Site
    Bad Homburg, 61348, Germany
  • Clinical Site
    Freiburg im Breisgau, 79104, Germany
  • Clinical Site
    Hamburg, 20253, Germany
  • Clinical Site
    Mittweida, 09648, Germany
  • Clinical Site
    Schwerin, 19053, Germany
  • Clinical Site
    Westerstede, 26655, Germany
  • Clinical Site
    Budapest, 1033, Hungary
  • Clinical Site
    Budapest, 1083, Hungary
  • Clinical Site
    Budapest, 1134, Hungary
  • Clinical Site
    Budapest, 1135, Hungary
  • Clinical Site
    Debrecen, 4032, Hungary
  • Clinical Site
    Gyöngyös, 3200, Hungary
  • Clinical Site
    Guwahati, Assam 781010, India
  • Clinical Site
    Ahmedabad, Gujarat 380013, India
  • Clinical Site
    Jūnāgadh, Gujarat 362001, India
  • Clinical Site
    Vadodara, Gujarat 390021, India
  • Clinical Site
    Mysore, Karnataka 570001, India
  • Clinical Site
    Aurangabad, Maharashtra 431005, India
  • Clinical Site
    Nagpur, Maharashtra 440010, India
  • Clinical Site
    Nashik, Maharashtra 422001, India
  • Clinical Site
    Mumbai, 400008, India
  • Clinical Site
    Nashik, 422005, India
  • Clinical Site
    Bełchatów, 97-400, Poland
  • Clinical Site
    Bialystok, 15-404, Poland
  • Clinical Site
    Bialystok, 15-464, Poland
  • Clinical Site
    Bialystok, 15-879, Poland
  • Clinical Site
    Bydgoszcz, 85-080, Poland
  • Clinical Site
    Gdansk, 80-546, Poland
  • Clinical Site
    Gorlice, 38-300, Poland
  • Clinical Site
    Leszno, 64-100, Poland
  • Clinical Site
    Pruszcz Gdański, 83-000, Poland
  • Clinical SIte
    Torun, 87-100, Poland
  • Clinical Site
    Wroclaw, 50-414, Poland
  • Clinical Site
    Bratislava, 82007, Slovakia
  • Clinical Site
    Košice, 04001, Slovakia
  • Clinical Site
    Rimavská Sobota, 979 01, Slovakia
  • Clinical Site
    Svidník, 089 01, Slovakia

Showing the first 100 of 109 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2024, 36 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 36 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Sep 29, 2021
StartActual
Oct 8, 2021
Primary completionActual
Oct 14, 2024
CompletionActual
Oct 23, 2024
Results first posted
Nov 3, 2025
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05061719
Responsible party
Sponsor
First posted
Sep 29, 2021
Start date
Oct 8, 2021
Primary completion
Oct 14, 2024
Completion
Oct 23, 2024
Results posted
Nov 3, 2025
Last update
Nov 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion